tiprankstipranks
Ascletis Pharma, Inc. (HK:1672)
:1672
Hong Kong Market
1672
Ascletis Pharma, Inc.
RESEARCH TOOLSreports
Want to see HK:1672 full AI Analyst Report?

Ascletis Pharma, Inc. (1672) Stock Forecast & Price Target

9 Followers
See the Price Targets and Ratings of:

1672 Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Ascletis
Pharma, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1672 Stock 12 Month Forecast

Average Price Target

HK$20.17
▲(9.15% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Ascletis Pharma, Inc. in the last 3 months. The average price target is HK$20.17 with a high forecast of HK$24.63 and a low forecast of HK$15.71. The average price target represents a 9.15% change from the last price of HK$18.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"HK$5","10":"HK$10","15":"HK$15","20":"HK$20","25":"HK$25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$24.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$20.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$15.71</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10,15,20,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.47,17.097692307692306,17.725384615384613,18.353076923076923,18.98076923076923,19.608461538461537,20.236153846153844,20.863846153846154,21.49153846153846,22.119230769230768,22.746923076923075,23.37461538461538,24.00230769230769,{"y":24.63,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.47,16.754615384615384,17.03923076923077,17.323846153846155,17.608461538461537,17.893076923076922,18.177692307692308,18.462307692307693,18.74692307692308,19.031538461538464,19.316153846153846,19.60076923076923,19.885384615384616,{"y":20.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.47,16.41153846153846,16.353076923076923,16.294615384615383,16.236153846153847,16.177692307692308,16.119230769230768,16.060769230769232,16.002307692307692,15.943846153846154,15.885384615384616,15.826923076923077,15.768461538461539,{"y":15.71,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.35,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.65,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.54,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.69,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$24.63Average Price TargetHK$20.17Lowest Price TargetHK$15.71
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Orient Securities Analyst forecast on HK:1672
Unknown Analyst
Orient Securities
Not Ranked
Orient Securities
HK$24.63
Buy
33.28%
Upside
Reiterated
04/06/26
Orient Securities Keeps Their Buy Rating on Ascletis Pharma, Inc. (1672)
Goldman Sachs Analyst forecast on HK:1672
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
HK$13.76→HK$15.71
Hold
-14.99%
Downside
Reiterated
04/02/26
Ascletis Pharma, Inc. (1672) Gets a Hold from Goldman Sachs
Citi Analyst forecast on HK:1672
Wangbin Zhou
Citi
Citi
HK$32
Buy
73.16%
Upside
Reiterated
02/03/26
Citi Reaffirms Their Buy Rating on Ascletis Pharma, Inc. (1672)
Guotai Haitong Analyst forecast on HK:1672
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$27.91
Buy
51.03%
Upside
Reiterated
08/17/25
Soochow Securities Analyst forecast on HK:1672
Unknown Analyst
Soochow Securities
Not Ranked
Soochow Securities
HK$29.26
Buy
58.33%
Upside
Reiterated
08/16/25
China Securities International Analyst forecast on HK:1672
Unknown Analyst
China Securities International
Not Ranked
China Securities International
HK$19.93
Buy
7.85%
Upside
Reiterated
06/26/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Orient Securities Analyst forecast on HK:1672
Unknown Analyst
Orient Securities
Not Ranked
Orient Securities
HK$24.63
Buy
33.28%
Upside
Reiterated
04/06/26
Orient Securities Keeps Their Buy Rating on Ascletis Pharma, Inc. (1672)
Goldman Sachs Analyst forecast on HK:1672
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
HK$13.76→HK$15.71
Hold
-14.99%
Downside
Reiterated
04/02/26
Ascletis Pharma, Inc. (1672) Gets a Hold from Goldman Sachs
Citi Analyst forecast on HK:1672
Wangbin Zhou
Citi
Citi
HK$32
Buy
73.16%
Upside
Reiterated
02/03/26
Citi Reaffirms Their Buy Rating on Ascletis Pharma, Inc. (1672)
Guotai Haitong Analyst forecast on HK:1672
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$27.91
Buy
51.03%
Upside
Reiterated
08/17/25
Soochow Securities Analyst forecast on HK:1672
Unknown Analyst
Soochow Securities
Not Ranked
Soochow Securities
HK$29.26
Buy
58.33%
Upside
Reiterated
08/16/25
China Securities International Analyst forecast on HK:1672
Unknown Analyst
China Securities International
Not Ranked
China Securities International
HK$19.93
Buy
7.85%
Upside
Reiterated
06/26/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascletis Pharma, Inc.

3 Months
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+14.90%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +14.90% per trade.
1 Year
Wangbin ZhouCiti
Success Rate
2/2 ratings generated profit
100%
Average Return
+22.45%
Copying Wangbin Zhou's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.45% per trade.
2 Years
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+22.45%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +22.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1672 Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
2
1
1
0
Buy
0
0
0
1
1
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
2
1
3
2
In the current month, 1672 has received 1 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1672 average Analyst price target in the past 3 months is 20.17.
Each month's total comprises the sum of three months' worth of ratings.

1672 Financial Forecast

1672 Earnings Forecast

Next quarter’s earnings estimate for 1672 is -HK$0.23 with a range of -HK$0.23 to -HK$0.23. The previous quarter’s EPS was -HK$0.32. 1672 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1672 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1672 is -HK$0.23 with a range of -HK$0.23 to -HK$0.23. The previous quarter’s EPS was -HK$0.32. 1672 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1672 has Performed in-line its overall industry.

1672 Sales Forecast

Next quarter’s sales forecast for 1672 is HK$0.00 with a range of HK$0.00 to HK$0.00. The previous quarter’s sales results were HK$1.04M. 1672 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1672 has Performed in-line its overall industry.
Next quarter’s sales forecast for 1672 is HK$0.00 with a range of HK$0.00 to HK$0.00. The previous quarter’s sales results were HK$1.04M. 1672 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1672 has Performed in-line its overall industry.

1672 Stock Forecast FAQ

What is HK:1672’s average 12-month price target, according to analysts?
Based on analyst ratings, Ascletis Pharma, Inc.’s 12-month average price target is 20.17.
    What is HK:1672’s upside potential, based on the analysts’ average price target?
    Ascletis Pharma, Inc. has 9.15% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ascletis Pharma, Inc. a Buy, Sell or Hold?
          Ascletis Pharma, Inc. has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Ascletis Pharma, Inc.’s share price target?
            The average share price target for Ascletis Pharma, Inc. is 20.17. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$24.63 ,and the lowest forecast is HK$15.71. The average share price target represents 9.15% Increase from the current price of HK$18.48.
              What do analysts say about Ascletis Pharma, Inc.?
              Ascletis Pharma, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Ascletis Pharma, Inc.?
                To buy shares of HK:1672, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.